Literature DB >> 18984364

A current review of topical benzoyl peroxide: new perspectives on formulation and utilization.

Emil A Tanghetti1, Karl F Popp.   

Abstract

Benzoyl peroxide (BPO) is the most widely used topical acne treatment, with significant antibacterial, antikeratolytic, and comedolytic activity. It has been shown to be extremely effective as monotherapy and in combination with antibiotics or retinoids for managing comedonal and inflammatory acne lesions. As numerous clinical studies have shown, the combination of BPO plus a topical antibiotic is not only more effective but also is often better tolerated than either agent alone. Unlike antibiotics, no bacterial resistance has been noted. Adding BPO to any long-term antibiotic regimen in acne is generally recommended to help reduce populations of drug-resistant variants. Although effective combinations of BPO and antibiotics or retinoids are used, BPO monotherapy can also be extremely effective in treating mild to moderate acne with no resistance issues.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18984364     DOI: 10.1016/j.det.2008.07.001

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  12 in total

1.  Benzoyl Peroxide Microsphere Formulations: What is the Science Supporting Microsphere Vehicle Technology and Clinical Use?

Authors: 
Journal:  J Clin Aesthet Dermatol       Date:  2009-09

2.  What is the Role of Benzoyl Peroxide Cleansers in Acne Management?: Do they Decrease Propionibacterium acnes Counts? Do they Reduce Acne Lesions?

Authors: 
Journal:  J Clin Aesthet Dermatol       Date:  2008-11

3.  A Meta-analysis to Investigate the Relation Between Fitzpatrick Skin Types and Tolerability of Adapalene-Benzoyl Peroxide Topical Gel in Subjects with Mild or Moderate Acne.

Authors:  Valerie D Callender; Norman Preston; Cris Osborn; Lori Johnson; Ronald W Gottschalk
Journal:  J Clin Aesthet Dermatol       Date:  2010-08

Review 4.  The Role of Skin Care as an Integral Component in the Management of Acne Vulgaris: Part 2: Tolerability and Performance of a Designated Skin Care Regimen Using a Foam Wash and Moisturizer SPF 30 in Patients with Acne Vulgaris Undergoing Active Treatment.

Authors:  James Q Del Rosso; Staci Brandt
Journal:  J Clin Aesthet Dermatol       Date:  2013-12

5.  In-vivo Effectiveness of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel on Antibiotic-sensitive and Resistant Propionibacterium acnes.

Authors:  James J Leyden; Norman Preston; Cris Osborn; Ronald W Gottschalk
Journal:  J Clin Aesthet Dermatol       Date:  2011-05

6.  Passive immunoprotection targeting a secreted CAMP factor of Propionibacterium acnes as a novel immunotherapeutic for acne vulgaris.

Authors:  Pei-Feng Liu; Teruaki Nakatsuji; Wenhong Zhu; Richard L Gallo; Chun-Ming Huang
Journal:  Vaccine       Date:  2011-02-26       Impact factor: 3.641

7.  The antimicrobial activity of liposomal lauric acids against Propionibacterium acnes.

Authors:  Darren Yang; Dissaya Pornpattananangkul; Teruaki Nakatsuji; Michael Chan; Dennis Carson; Chun-Ming Huang; Liangfang Zhang
Journal:  Biomaterials       Date:  2009-08-08       Impact factor: 12.479

8.  A review of the safety and efficacy of benzoyl peroxide (5.3%) emollient foam in the management of truncal acne vulgaris.

Authors:  Joseph Bikowski
Journal:  J Clin Aesthet Dermatol       Date:  2010-11

9.  In vivo treatment of Propionibacterium acnes infection with liposomal lauric acids.

Authors:  Dissaya Pornpattananangkul; Victoria Fu; Soracha Thamphiwatana; Li Zhang; Michael Chen; James Vecchio; Weiwei Gao; Chun-Ming Huang; Liangfang Zhang
Journal:  Adv Healthc Mater       Date:  2013-03-12       Impact factor: 9.933

10.  Acne Vulgaris and the Epidermal Barrier: Is Acne Vulgaris Associated with Inherent Epidermal Abnormalities that Cause Impairment of Barrier Functions? Do Any Topical Acne Therapies Alter the Structural and/or Functional Integrity of the Epidermal Barrier?

Authors:  Diane Thiboutot; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.